title: Gestational choriocarcinoma.
authors.affiliation: Department of Medical Oncology, Charing Cross Hospital, London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Bower
authors.forename: C
authors.initials: C
authors.lastname: Brock
authors.forename: R A
authors.initials: RA
authors.lastname: Fisher
authors.forename: E S
authors.initials: ES
authors.lastname: Newlands
authors.forename: G J
authors.initials: GJ
authors.lastname: Rustin
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002822:Choriocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D006063:Chorionic Gonadotropin / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage; D049590:Postpartum Period; D011247:Pregnancy; D011379:Prognosis; D013125:Spinal Neoplasms / Q000556:secondary; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D006063:Chorionic Gonadotropin; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate